BCAT-IN-4 Secrets
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositi